| | |
Mark to Market | Mobis Philipose and Ravi Ananthanarayanan 09:54 PM | September 14,2009
The pharmaceutical company’s calendar 2008 consolidated balance sheet had a debt of Rs1,302 crore against a net worth of Rs415 crore
|
|
Mark to Market | Manas Chakravarty and Ravi Ananthanarayanan 09:05 PM | August 19,2009
In all, the company has seven drugs in the pipeline. Even if a few reach the market, they could make up for all the money and effort spent
|
|
01:00 PM | November 20,2008
Azathioprine is a generic version of Imuran, used to prevent rejection in kidney transplantation
|
|
C.H. Unnikrishnan 09:13 PM | October 27,2008
For the quarter ending 30 September, Glenmark’s revenues grew 49.30% to Rs559.71 crore
|
|
C.H. Unnikrishnan and Radhieka Pandeya 10:29 PM | October 24,2008
Glenmark shares fall 20%; suspension may put a question mark on licensing deal with Eli Lilly for pain molecule
|
|
C.H. Unnikrishnan 12:30 AM | July 31,2007
An increase in foreign business made total sales rise 88% to Rs359.42 crore
|
|